Toggle Health Problems and D

Cancer not treated by Vitamin D when ignore dose size, type, and length of trial – meta-analysis April 2018

Cancer and vitamin D supplementation: a systematic review and meta-analysis

The American Journal of Clinical Nutrition, Volume 107, Issue 4, 1 April 2018, Pages 652–663, https://doi.org/10.1093/ajcn/nqx047
Beatriz Goulão Fiona Stewart John A Ford Graeme MacLennan Alison Avenell


They ignored

  • Dose Size: They gave 42% of the weight to a single trial with only 800 IU of vitamin D
    • Probably because that single trial had the highest Cancer incidence
  • Types - included Vitamin D2, active vitamin D, and Vitamin D analogs
  • Vitamin D level achieved (which is a function of both dose size and trial duration)

Cancer category starts with the following

Cancers get less Vitamin D when there is a poor Vitamin D Receptor

Background: Low 25-hydroxyvitamin D status has been associated with a higher risk of cancer in epidemiologic studies.

Objective: The aim of this study was to undertake a systematic review and meta-analysis of randomized clinical trials (RCTs) investigating the effect of vitamin D supplementation alone on cancer incidence and mortality.

A systematic review was undertaken. MEDLINE, Embase, CENTRAL, conference abstracts, and clinical trial registries were searched (last search March 2017) for RCTs investigating vitamin D supplementation alone. RCTs with ≥12 mo of follow-up and in participants with a mean or median age ≥60 y were eligible. During-study events were used as the main analysis, but after-study events were included in a secondary analysis. Subgroup analyses concerning different forms of vitamin D supplementation, 25-hydroxyvitamin D status at baseline, vitamin D dose, and exclusion of open-label trials were undertaken.

Thirty studies in 18,808 participants were included in the systematic review, with a median follow-up ranging from 1 to 6.2 y. The results of the meta-analysis for during-study events showed no evidence of an effect of vitamin D supplementation for cancer incidence (RR: 1.03; 95% CI: 0.91, 1.15) and cancer-related deaths (RR: 0.85; 95% CI: 0.70, 1.04). Including after-study events, the RRs were 1.02 (95% CI: 0.92, 1.13) and 0.85 (95% CI: 0.72, 1.00), respectively. These results did not appear to be affected by baseline 25-hydroxyvitamin D status, vitamin D dose, or the exclusion of open-label trials.

We did not find evidence to suggest that vitamin D supplementation alone reduces the incidence of cancer or cancer mortality, even after including long-term follow-up results.

Created by admin. Last Modification: Monday April 9, 2018 18:56:15 GMT-0000 by admin. (Version 4)